Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Raised by Tidal Investments LLC

Tidal Investments LLC boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 265.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,576 shares of the biopharmaceutical company's stock after acquiring an additional 14,947 shares during the period. Tidal Investments LLC's holdings in Halozyme Therapeutics were worth $1,178,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. World Investment Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth about $3,293,000. Sanctuary Advisors LLC raised its stake in Halozyme Therapeutics by 80.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 37,039 shares of the biopharmaceutical company's stock valued at $2,120,000 after acquiring an additional 16,511 shares during the last quarter. Virtu Financial LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth approximately $434,000. M&T Bank Corp grew its stake in shares of Halozyme Therapeutics by 0.5% in the 3rd quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company's stock valued at $6,367,000 after purchasing an additional 561 shares during the last quarter. Finally, Chiron Investment Management LLC raised its stake in shares of Halozyme Therapeutics by 23.6% during the third quarter. Chiron Investment Management LLC now owns 23,502 shares of the biopharmaceutical company's stock worth $1,345,000 after purchasing an additional 4,491 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Trading Down 0.8 %

Shares of Halozyme Therapeutics stock traded down $0.36 during trading hours on Friday, reaching $46.96. 4,794,681 shares of the company's stock were exchanged, compared to its average volume of 1,379,155. The firm has a market capitalization of $5.97 billion, a price-to-earnings ratio of 15.55, a price-to-earnings-growth ratio of 0.43 and a beta of 1.23. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a fifty day moving average of $51.03 and a 200-day moving average of $54.04.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 30,000 shares of company stock worth $1,621,800 in the last 90 days. 2.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on HALO shares. JMP Securities boosted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. Piper Sandler upped their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a report on Monday, November 4th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and upped their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. HC Wainwright reaffirmed a "buy" rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a report on Wednesday. Finally, Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.